We describe the case of a young woman with a known history of thrombocytopenia, who developed respiratory and circulatory failure thought to be caused by sepsis. She subsequently was shown to have high titres of anticardiolipin antibodies as well as lupus anticoagulant. Serological tests for various connective tissue diseases were negative. Multiple cerebral ischaemic lesions led to a poor outcome. This case highlights the potential difficulties in differentiating catastrophic anti-phospholipid syndrome from disseminated intravascular coagulation.
Devastating non-inflammatory vasculopathy was first described in two patients with anti-cardiolipin antibodies in 1987 1 . Two similar cases published a few years later called the condition "catastrophic occlusion syndrome" 2 . A review of 31 patients in the early 1990s led to the term of "catastrophic" antiphospholipid syndrome, to highlight the potentially life-threatening nature of the condition 3 . The difference in the pathology of these patients from the more usual chronic anti-phospholipid syndrome form seemed to be that large vessel arterial or venous involvement was uncommon and that microvascular involvement affecting many organs in various combinations was the predominant feature.
More recently a comprehensive review of the clinical and laboratory features of 50 patients compiled from the English, French and Spanish literature was published 4 . We describe a further case confirming the potential difficulties in diagnosis leading to delays in therapy with potential tragic sequelae.
CASE HISTORY
A 38-year-old female of southern European origin was admitted to our Level 3 intensive care unit with fever, non-productive cough, dyspnoea and a lung infiltrate. A diagnosis of pneumonia was made and shortly thereafter she required mechanical ventilation because of worsening hypoxaemia.
Her past medical history was of vitiligo from an early age. She had a smoking history of 20 pack years. Four years previously she consulted a neurologist for persistent headaches, blurred vision, vertigo, anorexia and nausea. Physical examination and head CT scan were normal. A mild thrombocytopenia of 98x10 9 /l was noted. A haematolgy opinion confirmed the low platelet count of 80 x10 9 /l. A diagnosis of immune thrombocytopenia was made after a bone marrow examination. There were no features of systemic lupus erythematosus. Three months later, chronic bronchitis was diagnosed, when she presented with haemoptysis. At that time her platelet count was 94x10 9 /l. Further episodes of haemoptysis in the 12 months prior to admission led to a bronchoscopy which was normal and a chest X-ray and CT scan, on the basis of which interstitial pneumonitis was diagnosed. The platelet count was stable between 80 and 90x10 9 /l.
Six months prior to admission she was seen by an ophthalmologist because of visual disturbance. A right quadrantic hemianopia was found and a brain CT scan showed a small area of parietal calcification, which was of uncertain significance. During this time a psychiatrist had also seen her for hysterical personality disorder, depression and social behaviour problems.
Following admission to ICU she developed pro-gressive circulatory failure requiring inotrope therapy (adrenaline 20 µg/min and dopamine 20 µg/kg/min). Insertion of pulmonary artery catheter revealed a haemodynamic pattern consistent with cardiogenic shock (CI 1.7 ml/min/m 2 , SVR 1800 dyn/s/cm 5 , with pulmonary artery occlusion pressure of 22 mmHg).
A transoesophageal echocardiograph (TOE) confirmed poor left ventricular function (Grade 2) with an estimated ejection fraction of 32%. Mitral valve regurgitation was noted as well as vegetations on the anterior mitral valve leaflet. Blood cultures were negative.
Over the next 48 hours, despite antibiotics, an extensive alveolar infiltrate was associated with worsening hypoxaemia and 72 hours after admission her P a O 2 : FiO 2 ratio was 82. Serum creatinine rose to 440 µmol/l, and renal replacement therapy (CVVHDH) was instituted. Liver dysfunction at this time was evident with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzyme levels of 2124 IU/l (N: 5 to 35 IU/l) and 2878 IU/l respectively, and bilirubin of 44 µmol/l (N: <17 µmol/l). Coagulation studies revealed an INR of 1.8 and an activated partial thromboplastin time (APTT) of 40 s (N: 24 to 34 s). In the laboratory, addition of normal plasma failed to correct the APTT. Fibrinogen levels were normal but fibrin degradation products were raised. The blood film did not show evidence of red cell fragmentation. The platelet count reached a nadir of 12 x10 9 /l on day 4. A skin biopsy of a rash on the lower extremities thought to be consistent with livedo reticularis confirmed multiple capillary thrombi. Tests for connective tissue disorders were negative, (anti-nuclear antibody doublestranded DNA 1.2 (N: 0 to 4.0 IU/ml), rheumatoid factor <20 IU/ml (N: 0 to 20 IU/ml), antineutrophilic cytoplasmic antibody (ANCA) not detected).
She was commenced on high-dose methylprednisolone, 1.0 g daily for 4 days, with gradual improvement and pulmonary function with resolution of her lung infiltrate. Circulatory failure improved 83 with gradual cessation of inotrope therapy on day 12. Renal replacement therapy was ceased on day 10 and a stable creatinine concentration of 160 µmol/l was maintained. Three days after cessation of all sedation, she remained obtunded with flexion/withdrawal to stimuli as the best neurological response. A brain CT scan showed extensive bilateral low attenuation lesions in occipital, parietal and frontal lobes consistent with extensive infarction (Figure 1) . A degree of cerebral atrophy was also noted. A neurological opinion confirmed a poor prognosis and she died two days later. A post mortem request was denied.
CASE REPORT
Anticardiolipin antibody (aCL) studies confirmed the presence of anti-phospholipid syndrome with IgM aCL being 28.7 IU/ml (N: 0 to 4.5 IU/ml) and IgG aCL 185 IU/ml (N: 0 to 5.5 IU/ml). Lupus anticoagulant (LAC) presence was also confirmed.
DISCUSSION
This patient presented with relatively sudden onset of multi-organ failure involving lungs, heart, kidneys, liver and brain. The possibility of sepsis secondary to bacterial endocarditis was the primary working diagnosis. However, this had to be reviewed in light of the skin biopsy and haematological findings.
TTP was not thought to be likely in view of the absence of red blood cell fragmentation and the presence of severe coagulation disturbance.
To differentiate this condition from disseminated intravascular coagulation (DIC) secondary to sepsis is difficult, as widespread microthrombosis and DIC may be a feature of both conditions. The current hypothesis for the development of catastrophic anti-phospholipid syndrome is that a sudden disturbance of the coagulation or fibrinolytic pathway is triggered by the anticardiolipin antibody as a result of endothelial cell molecules being exposed as well as platelet activation and increased glycoprotein expression 5 . Other platelet specific antibodies not directed against glycoproteins, i.e. other than anti-phospholipid antibodies, appear to play a role in the pathogenesis of the thrombocytopaenia in anti-phospholipid syndrome 6 . The primary target antigen however, appears to be β 2 GPI, a plasma protein with anticoagulant properties. The β 2 GPI undergoes a conformational change upon binding to negatively charged phospholipids and the resulting neo-epitopes are thought to be responsible for the anti-cardiolipin antibody binding 7 .
The authors of the early reported cases 1,2 suggested an active underlying rheumatic disorder. Recently however, the suggestion has been made that this is a haematological emergency thrombotic storm 8 and that aggressive anticoagulant therapy to prevent further vital organ blood flow compromise is mandatory, i.e. thrombosis begets thrombosis.
Whilst the prolonged APTT and abnormal INR were consistent in our case, with DIC, the lack of correction of the APTT with addition of an equal quantity of normal plasma suggested the presence of LAC. The abnormal INR was a reflection of liver dysfunction. The thrombin time, a phospholipid independent coagulation test, is not disturbed in the presence of LAC.
The clinical features demonstrated were consistent with the catastrophic primary anti-phospholipid syndrome described by Asherson in 1996 4 . A high female predominance with renal and lung involvement, mainly ARDS, were features in that series. Cardiac involvement was present in 50% of cases with 32% having valve involvement. The patient's marantic (non-bacterial thrombotic) endocarditis was therefore not so surprising. Central nervous system involvement however was not a feature, being more common in uncomplicated anti-phospholipid syndrome. This patient, on the other hand, showed extensive evidence of brain infarction involving areas supplied by large and small vessels. In Asherson's series, the presence of LAC and aCL antibodies, in particular high IgG aCL antibodies was >90%. Mortality was 50% with cardiac causes being predominant.
Although uncommon, this condition requires high clinical awareness because of the potential for rapid clinical deterioration and the need for specific therapy. Treatment is currently of an empirical nature. The combination of anticoagulation, steroids and attempts to reduce the aPL titer with plasmapharesis are the available treatment options. Intravenous gamma globulin has been used as an adjunct therapy as has ancrod, which has been shown to correct prostacyclin stimulating factor and vascular plasminogen activator deficiency 9 . Ancrod is a purified fraction of snake venom that induces rapid de-fibrinogenation by splitting fibrinopeptide A from fibrinogen.
The presence of thrombocytopenia, and/or a prolonged APTT, which does not correct with normal plasma, should trigger awareness of the potential problem of anti-phospholipid syndrome, particularly in someone with a history of thrombosis or recurrent foetal loss. This condition, although often associated with systemic lupus erythematosus, can present de novo in a catastrophic manner and the critical care physician needs to be aware of it.
